Cargando…

Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19

Humanized Virus Suppressing Factor-variant 13 (hzVSF-v13), a monoclonal IgG4 antibody against vimentin, was investigated in moderate to severe COVID-19 pneumonia through a Phase II study. Patients were randomized to two different IV doses of the test drug or saline with standard of care. Overall, 64...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasenohadi, Prasenohadi, Burhan, Erlina, Dhunny, Sri, Suharno, Wahyuningsih, Wabnitz, Paul, Kim, Yoon-Won, Petrosillo, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181020/
https://www.ncbi.nlm.nih.gov/pubmed/35683351
http://dx.doi.org/10.3390/jcm11112961
_version_ 1784723664324788224
author Prasenohadi, Prasenohadi
Burhan, Erlina
Dhunny, Sri
Suharno, Wahyuningsih
Wabnitz, Paul
Kim, Yoon-Won
Petrosillo, Nicola
author_facet Prasenohadi, Prasenohadi
Burhan, Erlina
Dhunny, Sri
Suharno, Wahyuningsih
Wabnitz, Paul
Kim, Yoon-Won
Petrosillo, Nicola
author_sort Prasenohadi, Prasenohadi
collection PubMed
description Humanized Virus Suppressing Factor-variant 13 (hzVSF-v13), a monoclonal IgG4 antibody against vimentin, was investigated in moderate to severe COVID-19 pneumonia through a Phase II study. Patients were randomized to two different IV doses of the test drug or saline with standard of care. Overall, 64 patients were recruited, and 62 entered the efficacy assessment in the full analysis set. Primary endpoint: The clinical failure rate at day 28 was 15.8% for placebo, 9.1% for low-dose hzVSF-v13 and 9.5% for high-dose hzVSF-v13 (not significant). A trend toward better efficacy was shown in several secondary endpoints, with statistical significance between low-dose hzVSF-v13 and placebo in terms of the rate of improved patients on the ordinal scale for clinical improvement (OSCI): 90.0% vs. 52.63% (p = 0.0116). In the severe stratum, the results of low-dose hzVSF-v13 vs. placebo were 90.0% and 22.2% for OSCI (p = 0.0092), 9 days and 14 days for time to discontinuation of oxygen therapy (p = 0.0308), 10 days and 15 days for both time to clinical improvement (TTCI) and time to recovery (TTR) and p = 0.0446 for both TTCI and TTR. Change from baseline of NEWS2 score at day 28 was −3.4 vs. + 0.4 (p = 0.0441). The results propose hzVSF-v13 as a candidate in the treatment of severe COVID-19.
format Online
Article
Text
id pubmed-9181020
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91810202022-06-10 Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19 Prasenohadi, Prasenohadi Burhan, Erlina Dhunny, Sri Suharno, Wahyuningsih Wabnitz, Paul Kim, Yoon-Won Petrosillo, Nicola J Clin Med Article Humanized Virus Suppressing Factor-variant 13 (hzVSF-v13), a monoclonal IgG4 antibody against vimentin, was investigated in moderate to severe COVID-19 pneumonia through a Phase II study. Patients were randomized to two different IV doses of the test drug or saline with standard of care. Overall, 64 patients were recruited, and 62 entered the efficacy assessment in the full analysis set. Primary endpoint: The clinical failure rate at day 28 was 15.8% for placebo, 9.1% for low-dose hzVSF-v13 and 9.5% for high-dose hzVSF-v13 (not significant). A trend toward better efficacy was shown in several secondary endpoints, with statistical significance between low-dose hzVSF-v13 and placebo in terms of the rate of improved patients on the ordinal scale for clinical improvement (OSCI): 90.0% vs. 52.63% (p = 0.0116). In the severe stratum, the results of low-dose hzVSF-v13 vs. placebo were 90.0% and 22.2% for OSCI (p = 0.0092), 9 days and 14 days for time to discontinuation of oxygen therapy (p = 0.0308), 10 days and 15 days for both time to clinical improvement (TTCI) and time to recovery (TTR) and p = 0.0446 for both TTCI and TTR. Change from baseline of NEWS2 score at day 28 was −3.4 vs. + 0.4 (p = 0.0441). The results propose hzVSF-v13 as a candidate in the treatment of severe COVID-19. MDPI 2022-05-24 /pmc/articles/PMC9181020/ /pubmed/35683351 http://dx.doi.org/10.3390/jcm11112961 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Prasenohadi, Prasenohadi
Burhan, Erlina
Dhunny, Sri
Suharno, Wahyuningsih
Wabnitz, Paul
Kim, Yoon-Won
Petrosillo, Nicola
Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19
title Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19
title_full Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19
title_fullStr Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19
title_full_unstemmed Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19
title_short Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19
title_sort double-blind, randomized, placebo-controlled study on hzvsf-v13, a novel anti-vimentin monoclonal antibody drug as add-on standard of care in the management of patients with moderate to severe covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181020/
https://www.ncbi.nlm.nih.gov/pubmed/35683351
http://dx.doi.org/10.3390/jcm11112961
work_keys_str_mv AT prasenohadiprasenohadi doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19
AT burhanerlina doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19
AT dhunnysri doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19
AT suharnowahyuningsih doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19
AT wabnitzpaul doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19
AT kimyoonwon doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19
AT petrosillonicola doubleblindrandomizedplacebocontrolledstudyonhzvsfv13anovelantivimentinmonoclonalantibodydrugasaddonstandardofcareinthemanagementofpatientswithmoderatetoseverecovid19